Pfizer shelves obesity pill plan after patient suffers liver injury during clinical trial

Pfizer shelves obesity pill plan after patient suffers liver injury during clinical trial

Pfizer Inc. has said it will discontinue development of its closely watched obesity pill, danuglipron, dealing a severe blow to the company’s ambitions to compete in the rapidly growing weight-loss drug market dominated by Novo Nordisk and Eli Lilly, according to a report

The Pfizer logo is seen outside the pharmaceutical company’s manufacturing plant, in Newbridge, Ireland on February 10, 2025. Reuters File